Clinical trials are how new treatments and improved outcomes are developed in health care. Highlands Oncology has been participating in clinical trials for over 26 years. Our Research Department operates numerous clinical trials in both oncology and hematology. New experimental medications, or different ways to use existing medications, are compared to the currently available treatments in order to advance cancer care for patients around the world.
Each clinical trial has certain criteria that must be met to participate. These guidelines help protect the safety of each patient. There are four phases of clinical trial development:
Phase I – Assessing medication dose and safety
Phase II – Further assessing safety and efficacy
Phase III – Comparison to currently available medications
Phase IV – Further study of already FDA-approved medications
Phase I clinical trials provide new, novel approaches for the treatment of cancer. Highlands Oncology has the privilege of being the only community based Phase I oncology clinical trial center in the state of Arkansas. Cancer research is always evolving and new treatments emerge every year. Highlands Oncology stays at the cutting edge of technology with help from the Research Department and clinical trials.
We strive to provide as many options as possible for the treatment of cancer. Only you and your doctor can decide if a clinical trial is right for you. If you are interested in participating in a clinical trial, please review our list of currently enrolling clinical trials. For further information on clinical trials, please visit http://www.clinicaltrials.gov.
For questions or more information, please contact the Research Department:
Seattle Genetics/SGNB6A-001/A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
SOLID TUMORS
10/16/2024
AbbVie/M19-345/A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of Livmoniplimab (ABBV-151) as a Single Agent and in Combination with Budigalimab (ABBV-181) in Subjects with Locally Advanced or Metastatic Solid Tumors
SOLID TUMORS
09/05/2024
Eli Lilly I3Y-MC-JPEG: CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
PROSTATE
07/26/2022
Stemline/MEN2312-01/A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer, 285057
BREAST
11/26/2024
AbbVie/M25-204/A Phase 2, Open-Label, Randomized Study of Livmoniplimab in Combination with Budigalimab Versus Chemotherapy in Subjects with Metastatic Urothelial Carcinoma
OTHER
12/05/2024
Pfizer/C5461001/A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF PF-07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS
SOLID TUMORS
10/24/2024
Genentech/ML45219/PHASE II, OPEN-LABEL, PROSPECTIVE SINGLE-ARM, MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI-MONOTHERAPY FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD
LEUKEMIA - Chronic Lymphocytic
11/14/2024
Stemline/STML-ELA-0422/Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
BREAST
12/10/2024
Pfizer/C5421001/A PHASE 1 OPEN-LABEL STUDY OF PF-07934040 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS
SOLID TUMORS
08/08/2024
AstraZeneca/D516KC00001/A Phase III, Open Label, Sponsor-Blind, Randomized Study of Dato DXd With or Without Osimertinib Versus Platinum-Based Doublet Chemotherapy for Patients with EGFR-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)
LUNG - Non Small Cell Cancer (NSCLC)
09/27/2024
Fulgent/FID-007-003/A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
HEAD/NECK
07/25/2024
Merck/MK2870-019/A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab with or without MK-2870 in Resectable Stage II to IIIB (N2) NSCLC for Participants not Achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum based Doublet Chemotherapy Followed by Surgery
LUNG - Non Small Cell Cancer (NSCLC)
11/11/2024
BostonGene/BGER001/A Prospective Study of Comprehensive Molecular Testing in Advanced Cancer Patients in the Community Setting
SOLID TUMORS
04/11/2024
Personalis/01-PS-001/Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)
BREAST
10/14/2024
Pfizer/C4891026/INTERVENTIONAL SAFETY AND EFFICACY PHASE 1b/2, OPEN-LABEL STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH PF-07220060 IN PARTICIPANTS AGED 18 years AND OLDER WITH ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER
BREAST
11/26/2024
Daiichi Sankyo/DS7300-188/A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physicians Choice (TPC) in Subjects with Relapsed Small Cell Lung Cancer (SCLC) (IDeate-2)
LUNG - Small Cell Cancer (SCLC)
07/18/2024
AstraZeneca / D9723C00001 / A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
PROSTATE
12/15/2023
Pfizer/Z0101001/A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation
COLORECTAL
09/10/2024
Pfizer/C4391022/AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4 or 6 INHIBITOR BASED THERAPY.
BREAST
06/25/2024
UAMS/EA5221/A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer - The ACHIEVE Study
LUNG - Non Small Cell Cancer (NSCLC)
10/18/2024
Alliance/A032103/MODERN: AN INTEGRATED PHASE 2/3 AND PHASE 3 TRIAL OF MRD-BASED OPTIMIZATION OF ADJUVANT THERAPY IN UROTHELIAL CANCER
UROTHELIAL
07/29/2024
UAMS/275695/A Phase II Clinical Trial of Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence (Candin)
HEAD/NECK
07/22/2024
AstraZeneca / D8535C00001 / CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as adjuvant treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
BREAST
01/18/2024
Merck / MK1026-010 / A randomized, study to compare the efficacy and safety of nemtabrutinib (MK-1026) plus venetoclax vx. Nenetoclax plus rituximab in participats with relapsed refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma following at least 1 prior therapy.
LEUKEMIA - Chronic Lymphocytic
09/19/2023
Novartis/CAAA617D12302/An International, Prospective, Open-label, Multi-center,Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan(AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)
PROSTATE
07/12/2024
Lantern Pharma / LTRN184-1AST23-1 / A PHASE 1A DOSE ESCALATION STUDY OF LP-184 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS
SOLID TUMORS
12/28/2023
Abbvie / M24-147 / A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab for locally advanced or Metastatic Hepatocellular Carcinoma (HCC) patients who have progressed after an approved immune checkpoint inhibitor containing regimen in 1L HCC
SOLID TUMORS
08/22/2023
All4Cure / A4C-002 / Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
MULTIPLE MYELOMA
04/11/2023
AbbVie/M24-108/A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma
MULTIPLE MYELOMA
12/10/2024
SWOG/S2114/A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
LYMPHOMA
07/24/2024
Southwest Oncology Group (SWOG) / S2302 / Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
LUNG - Non Small Cell Cancer (NSCLC)
08/22/2023
AstraZeneca D926XC00001 – A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)
BREAST
02/15/2023
Bristol-Myers Squibb/CA224-127/A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
MELANOMA
08/01/2024
Merck / MK1026-008 / A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations (BELLWAVE-008)
LEUKEMIA - Chronic Lymphocytic
10/03/2023
Stemline STML-ELA-0322 – ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer: An Open-Label Multicenter Phase 2 Study (ELCIN)
BREAST
07/26/2023
Stemline STML-ELA-0222 – A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
BREAST
07/27/2023
NRG Oncology/NRG-GY028/A Phase IB and Randomized Phase II Trial of Megestrol Acetate with or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer
ENDOMETRIAL
09/23/2024
Shanghai Henlius Biotech / HLX10-020-SCLC302 / A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)
LUNG - Small Cell Cancer (SCLC)
11/15/2023
Delfi Diagnostics/DELFI-L101/DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study. DELFI-L101 Study
LUNG - Non Small Cell Cancer (NSCLC)
12/02/2024
AstraZeneca D926NC00001 Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin for First-Line Treatment of Patients With Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)
LUNG - Non Small Cell Cancer (NSCLC)
05/25/2023
Pfizer C4901001: A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
SOLID TUMORS
11/11/2022
Shanghai Henlius Biotech HLX10-005-SCLC301-E: A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
LUNG - Small Cell Cancer (SCLC)
12/12/2022
Eli Lilly J2J-MC-JZLH: EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
BREAST
11/22/2022
Revolution Medicines RMC-6291-001: Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
LUNG - Non Small Cell Cancer (NSCLC)
10/24/2022
Ascentage Pharma APG-5918XG101: A Phase I Study of Safety, Pharmacokinetic and Efficacy of Orally Administered APG-5918 in Patients With Advanced Solid Tumors or Hematologic Malignancies
OTHER
10/13/2022
iTEOS A2A-005: Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
LUNG - Non Small Cell Cancer (NSCLC)
08/08/2022
Pfizer C4761001- A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS
MELANOMA
05/26/2022
Imugene CF33-hNIS-002: This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS – human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab in patients with metastatic or advanced solid tumors.
SOLID TUMORS
01/05/2023
Daiichi Sankyo: U31402-A-U301- A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
LUNG - Non Small Cell Cancer (NSCLC)
06/08/2022
Bristol-Myers Squibb: CA224-123 – A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123)
COLORECTAL
06/03/2022
Daiichi Sankyo DS7300-127: A Phase 2, Multicenter, Randomized, Open-label Study of DS-7300a, a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)
LUNG
01/11/2023
Freenome FRNM-008: The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
OTHER
12/27/2022
Eli Lilly I3Y-MC-JPEF: A Phase 3: Randomized, Double Blind: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Advanced or Metastatic Breast, HR+, HER2-, following progression on a CDK 4/6 Inhibitor and Endocrine Therapy.
BREAST
01/10/2022
Novartis CLEE011A2412B: A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study
BREAST
07/07/2022
Gritstone Bio, Inc. GO-010: A Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer.
COLORECTAL
04/18/2022
Guardant 02-MX-002 SHIELD – Screening for High Frequency Malignant Disease (SHIELD)
LUNG
08/08/2022
AstraZeneca D967RC00001: A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)
BREAST
01/26/2023
TG Therapeutics TG-1801-102: “A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination with Ublituximab in Subjects with B-Cell Lymphoma or Chronic Lymphocytic Leukemia”
LEUKEMIA - Chronic Lymphocytic
04/07/2021
Mirati Therapeutics 849-010: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
COLORECTAL
03/15/2021
AstraZeneca D967UC00001: Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)
BREAST
01/03/2022
Merck MK1026-003: A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies
OTHER
02/02/2023
AstraZeneca D8532C00001 (SERENA-4): A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.
BREAST
12/06/2021
Sarah Cannon BRE-354: A Phase II Study of U3-1402 in Patients With Metastatic Breast Cancer
BREAST
10/21/2022
Mirati Therapeutics Inc. 849-007: Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7.
LUNG - Non Small Cell Cancer (NSCLC)
11/02/2021
Seagen Inc., SGN35-033: A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies After Progression on Prior PD-1 Inhibitor Treatment
MELANOMA
10/17/2022
Abbvie M20-178: A Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2).
MYELOFIBROSIS
10/02/2020
Pfizer: C4201002 – A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF 07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES.
SOLID TUMORS
05/19/2022
AbbVie M20-124: A Phase 1, Multi-center, Open Label First-in-Human Study with ABBV-CLS-579 Alone and in Combination with Anti-PD-1 in Subjects with Locally Advanced or Metastatic Tumors
SOLID TUMORS
03/01/2021
OncoC4 ONC-392-001: Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
OTHER
10/28/2022
Immunomedics IMMU-132-11: A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors
SOLID TUMORS
06/16/2021
AbbVie M19-037: A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors
OTHER
07/14/2020
Ascentage Pharma APG-115-US-002: A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
OTHER
09/10/2019
AbbVie M14-239: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
LUNG - Non Small Cell Cancer (NSCLC)
03/11/2020
Takeda TAK573-1501: A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
MULTIPLE MYELOMA
06/03/2022
Southwest Oncology Group (SWOG) S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
OTHER
04/10/2018
Pfizer/C4891024/TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
BREAST
02/23/2024
Eli Lilly/J3M-MC-JZQB/A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C
LUNG - Non Small Cell Cancer (NSCLC)
02/02/2024
AstraZeneca/D7630C00001/A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
BREAST
06/05/2024
Merck/MK-3475A-F11/A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated with Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types (MK-3475A-F11)
SOLID TUMORS
01/24/2024
AstraZeneca/D798AC00001/A Phase III, Two-Arm, Parallel, Randomized, Multi-Center,Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) (eVOLVE-Lung02)
LUNG - Non Small Cell Cancer (NSCLC)
06/06/2024
Merck/V940-001/A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma
MELANOMA
02/06/2024
AbbVie/M23-362/A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma